Sung‐Bae Kim - Concepedia

Author

Sung‐Bae Kim

Also Known As

Badwe, Rajendra A., Charles Kelly, Gyungyub Gong, Jae-Lyun Lee, Jin-Hee Ahn, Kim, Sung-Bae, Kim,Sung-Bae, Kyung-Ja Cho, S.-B. Kim, S.B. Kim

716

Publications

41.4K

Citations

H-Index

187

Concepts

All Affiliations

University of Ulsan Asan Medical Center Ulsan College Samsung Medical Center Seoul National University Hospital

About

Sung‐Bae Kim is an author at University of Ulsan specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	49	127	17.4K
2	Health Sciences	29	47	6.7K
3	Engineering	12	12	472
4	Allergy	2	2	43
5	Social Sciences	1	1	14

Sung‐Bae Kim

278

Publications

39.3K

Citations

H-Index

Page 1

	Year	Citations
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, Javier Cortés, Sung‐Bae Kim, New England Journal of Medicine	2011	2.5K
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi, William Jacot, Toshinari Yamashita, New England Journal of Medicine	2022	2.3K
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Sandra M. Swain, José Baselga, Sung‐Bae Kim, New England Journal of Medicine	2015	2.1K
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer Martin Schlumberger, Makoto Tahara, Lori J. Wirth, New England Journal of Medicine	2015	2K
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi, Cristina Saura, Toshinari Yamashita, New England Journal of Medicine	2019	1.9K
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, New England Journal of Medicine	2017	1.8K
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, The Lancet MedicinePathologyHead And Neck CancerCancer TreatmentNeck Oncology	2018	1.6K
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Jong‐Mu Sun, Lin Shen, Manish A. Shah, The Lancet Chemotherapy Versus ChemotherapyOncologyEsophageal CancerGastrointestinal OncologyClinical Trials	2021	1.5K
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Ken Kato, Byoung Chul Cho, Masanobu Takahashi, The Lancet Oncology Esophageal CancerGastrointestinal OncologyMedicinePrevious ChemotherapyNivolumab Versus Chemotherapy	2019	1.2K
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Takashi Kojima, Manish A. Shah, Kei Muro, Journal of Clinical Oncology	2020	1.1K

Page 1